Screening suspect pharmaceuticals for illicit designer benzodiazepines using raman, SERS, and FT-IR prior to comprehensive analysis using LC-MS

被引:9
作者
Kimani, Martin M. [1 ]
Smith, Skyler W. [1 ]
Lanzarotta, Adam [1 ]
Brueggemeyer, Jana L. [1 ]
Batson, JaCinta S. [1 ]
机构
[1] US FDA, Off Regulatory Affairs, Off Regulatory Sci, Forens Chem Ctr, Cincinnati, OH 45237 USA
关键词
Illicit drugs; Designer benzodiazepines; Trace drug analysis; Raman; FT-IR; SERS; Handheld Raman devices; LC-MS; FOURIER-TRANSFORM RAMAN; SPECTROSCOPY; METABOLISM; STATES;
D O I
10.1016/j.forsciint.2022.111390
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The emergence of illicit designer benzodiazepines with high dependency and no approved clinical use are of great US public health concern. Due to the increasing numbers of illicit designer benzodiazepines en-countered in the US supply chain, there is a need to develop robust analytical methods that can rapidly detect these chemicals. Suspect counterfeit tablets, powders, or liquid formulations were first screened using Raman spectroscopy and surface-enhanced Raman scattering spectroscopy (SERS) for the presence of legal or illicit benzodiazepines, and then further analyzed using Fourier-transform infrared (FT-IR) spec-troscopy and liquid chromatography with tandem mass spectrometric detection (LC-MS). Several micro -extraction procedures were developed and used to extract benzodiazepines from samples prior to SERS, FT-IR, and LC-MS analysis. Conventional Raman analyses using handheld Raman spectrometers afforded the ability to examine samples through enclosed plastic bags but were only able to detect high concentrations of various benzodiazepines in the suspect samples. The developed SERS methods were sufficient for de-tecting at least one benzodiazepine in the low-dose suspect samples, thereby allowing prioritization using other analytical tools that require more sample preparation and time-consuming analyses. The use of FT-IR spectroscopy coupled with extraction and spectral subtraction was found to be selective to multiple ben-zodiazepines and various excipients in the analyzed samples. This study demonstrated that the developed SERS and FT-IR procedures could be used in satellite laboratories to screen suspect packages at ports of entry and prioritize samples for additional laboratory-based analyses in an effort to prevent dangerous and illicit pharmaceutical products from reaching the US supply chain.Published by Elsevier B.V.
引用
收藏
页数:10
相关论文
共 37 条
  • [1] Adair A., 1983, MICROGRAM, VXVI, P220
  • [2] [Anonymous], H.R.6 - SUPPORT for Patients and Communities Act
  • [3] Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013
    Bachhuber, Marcus A.
    Hennessy, Sean
    Cunningham, Chinazo O.
    Starrels, Joanna L.
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2016, 106 (04) : 686 - 688
  • [4] Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
    Bergstrand, Madeleine Pettersson
    Helander, Anders
    Hansson, Therese
    Beck, Olof
    [J]. DRUG TESTING AND ANALYSIS, 2017, 9 (04) : 640 - 645
  • [5] Brunton LL., 2005, GOODMAN GILLMANS PHA, V11th
  • [6] New benzodiazepines for sedation
    Cornett, Elyse M.
    Novitch, Matthew B.
    Brunk, Andrew J.
    Davidson, Kelly S.
    Menard, Bethany L.
    Urman, Richard D.
    Kaye, Alan D.
    [J]. BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY, 2018, 32 (02) : 149 - 164
  • [7] CHEMOMETRIC CRITERIA FOR ASSESSING THE CERTAINTY OF QUALITATIVE ANALYTICAL METHODS
    DERUIG, WG
    DIJKSTRA, G
    STEPHANY, RW
    [J]. ANALYTICA CHIMICA ACTA, 1989, 223 (01) : 277 - 282
  • [8] EMCDDA, 2018, PERSPECTIVE DRUGS MI
  • [9] Erika L.D., 2014, THESES, P1642
  • [10] Rapid and accurate etizolam detection using surface-enhanced Raman spectroscopy for community drug checking
    Gozdzialski, Lea
    Rowley, Annabel
    Borden, Scott A.
    Saatchi, Armin
    Gill, Chris G.
    Wallace, Bruce
    Hore, Dennis K.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 102